Effect of Secreted Molecules of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells on Acute Hepatic Failure Model

Stem Cells and Development

Volumn 25, Issue 24, 2016, Pages 1898-1908

  Lotfinia, Majid ^a   Kadivar, Mehdi ^a   Piryaei, Abbas ^b,c   Pournasr, Behshad ^b   Sardari, Soroush ^a   Sodeifi, Niloofar ^b   Sayahpour, Forugh Azam ^b   Baharvand, Hossein ^b,d  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SCIENCE AND CULTURE   (Iran)

Author keywords

acute liver failure; embryonic stem cells; mesenchymal stem cells; secretome; soluble factors; VEGF

Indexed keywords

CELL SURFACE MARKER; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; THIOACETAMIDE; VASCULOTROPIN; CONDITIONED MEDIUM; PROTEOME;

ACUTE LIVER FAILURE; ADIPOGENESIS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONDITIONED MEDIUM; CONTROLLED STUDY; CYTOKINE RELEASE; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; IN VITRO STUDY; INFANT; LIVER CELL; LIVER INJURY; MALE; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN MICROARRAY; THERAPY EFFECT; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL LINE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; IMMUNOMODULATION; LIVER FAILURE, ACUTE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHARMACOLOGY; PROTEOMICS; SECRETION (PROCESS);

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; HEPATOCYTES; HUMAN EMBRYONIC STEM CELLS; HUMANS; IMMUNOMODULATION; LIVER FAILURE, ACUTE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; PROTEOME; PROTEOMICS;

EID: 85004000431     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2016.0244     Document Type: Article

References (32)

1. Dhaliwal HS and P Singh. (2014). Acute liver failure. N Engl J Med 370:1170.
2. Miwa S, Y Hashikura, A Mita, T Kubota, H Chisuwa, Y Nakazawa, T Ikegami, M Terada, S Miyagawa and S Kawasaki. (1999). Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure. Hepatology 30:1521-1526.
3. Irfan A and I Ahmed. (2015). Could stem cell therapy be the cure in liver cirrhosis? J Clin Exp Hepatol 5:142-146.
4. Owen A and PN Newsome. (2015). Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt? Am J Physiol Gastrointest Liver Physiol 309:G791-G800.
5. Keating A. (2012). Mesenchymal stromal cells: new directions. Cell Stem Cell 10:709-716.
6. Liu Z, F Meng, C Li, X Zhou, X Zeng, Y He, RJ Mrsny, M Liu, X Hu, JF Hu and T Li. (2014). Human umbilical cord mesenchymal stromal cells rescue mice from acetaminopheninduced acute liver failure. Cytotherapy 16:1207-1219.
7. Christ B, S Bruckner and S Winkler. (2015). The therapeutic promise of mesenchymal stem cells for liver restoration. Trends Mol Med 21:673-686.
8. van Poll D, B Parekkadan, CH Cho, F Berthiaume, Y Nahmias, AW Tilles and ML Yarmush. (2008). Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47:1634-1643.
9. Parekkadan B, D van Poll, K Suganuma, EA Carter, F Berthiaume, AW Tilles and ML Yarmush. (2007). Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2:e941.
10. Gadkari R, L Zhao, T Teklemariam and BM Hantash. (2014). Human embryonic stem cell derived-mesenchymal stem cells: an alternative mesenchymal stem cell source for regenerative medicine therapy. Regen Med 9:453-465.
11. Sanchez L, I Gutierrez-Aranda, G Ligero, R Rubio, M Munoz-Lopez, JL Garcia-Perez, V Ramos, PJ Real, C Bueno, et al. (2011). Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells 29:251-262.
12. Ferrer L, EA Kimbrel, A Lam, EB Falk, C Zewe, T Juopperi, R Lanza and A Hoffman. (2016). Treatment of perianal fistulas with human embryonic stem cell-derived mesenchymal stem cells: a canine model of human fistulizing Crohn's disease. Regen Med 11:33-43.
13. Wang X, EA Kimbrel, K Ijichi, D Paul, AS Lazorchak, J Chu, NA Kouris, GJ Yavanian, SJ Lu, et al. (2014). Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports 3:115-130.
14. Baharvand H, SK Ashtiani, A Taee, M Massumi, MR Valojerdi, PE Yazdi, SZ Moradi and A Farrokhi. (2006). Generation of new human embryonic stem cell lines with diploid and triploid karyotypes. Dev Growth Differ 48: 117-128.
15. Hwang NS, S Varghese, HJ Lee, Z Zhang, Z Ye, J Bae, L Cheng and J Elisseeff. (2008). In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc Natl Acad Sci USA 105:20641-20646.
16. Mohamadnejad M, K Alimoghaddam, M Mohyeddin-Bonab, M Bagheri, M Bashtar, H Ghanaati, H Baharvand, A Ghavamzadeh and R Malekzadeh. (2007). Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 10:459-466.
17. Olivier EN, AC Rybicki and EE Bouhassira. (2006). Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells. Stem Cells 24:1914-1922.
18. Shen L, A Hillebrand, DQ Wang and M Liu. (2012). Isolation and primary culture of rat hepatic cells. J Vis Exp pii: 3917.
19. Jiao J, JM Milwid, ML Yarmush and B Parekkadan. (2011). A mesenchymal stem cell potency assay. Methods Mol Biol 677:221-231.
20. Tahamtani Y, M Azarnia, A Farrokhi, A Sharifi-Zarchi, N Aghdami and H Baharvand. (2013). Treatment of human embryonic stem cells with different combinations of priming and inducing factors toward definitive endoderm. Stem Cells Dev 22:1419-1432.
21. Ishak K, A Baptista, L Bianchi, F Callea, J De Groote, F Gudat, H Denk, V Desmet, G Korb, et al. (1995). Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699.
22. Schnabel LV, CM Abratte, JC Schimenti, MJ Felippe, JM Cassano, TL Southard, JA Cross and LA Fortier. (2014). Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro. Regen Med 9:621-635.
23. Milwid JM, JS Elman, M Li, K Shen, A Manrai, A Gabow, J Yarmush, Y Jiao, A Fletcher, et al. (2014). Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther 22:999-1007.
24. Takada Y, T Hisamatsu, N Kamada, MT Kitazume, H Honda, Y Oshima, R Saito, T Takayama, T Kobayashi, et al. (2010). Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset. J Immunol 184:2671-2676.
25. Hettmer S, L Dannecker, J Foell, MW Elmlinger and GE Dannecker. (2005). Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells. Hum Immunol 66:95-103.
26. Do N, R Zhao, K Ray, K Ho, M Dib, X Ren, P Kuzontkoski, E Terwilliger and SJ Karp. (2012). BMP4 is a novel paracrine inhibitor of liver regeneration. Am J Physiol Gastrointest Liver Physiol 303:G1220-G1227.
27. Fan J, H Shen, Y Sun, P Li, F Burczynski, M Namaka and Y Gong. (2006). Bone morphogenetic protein 4 mediates bile duct ligation induced liver fibrosis through activation of Smad1 and ERK1/2 in rat hepatic stellate cells. J Cell Physiol 207:499-505.
28. Tsugawa D, Y Oya, R Masuzaki, K Ray, DW Engers, M Dib, N Do, K Kuramitsu, K Ho, et al. (2014). Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J Pharmacol Exp Ther 351:549-558.
29. Johnson BF, TM Clay, AC Hobeika, HK Lyerly and MA Morse. (2007). Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 7:449-460.
30. Chen L, Y Xu, J Zhao, Z Zhang, R Yang, J Xie, X Liu and S Qi. (2014). Conditioned medium from hypoxic bone marrow-derived mesenchymal stem cells enhances wound healing in mice. PLoS One 9:e96161.
31. Banas A, T Teratani, Y Yamamoto, M Tokuhara, F Takeshita, M Osaki, M Kawamata, T Kato, H Okochi and T Ochiya. (2008). IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells 26:2705-2712.
32. Zagoura DS, MG Roubelakis, V Bitsika, O Trohatou, KI Pappa, A Kapelouzou, A Antsaklis and NP Anagnou. (2012). Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut 61:894-906.